Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...
Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...
Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics ...
Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment ...
Recent approvals and settlements enhance global access to aflibercept biosimilars, improving treatment options for ...
The European Commission (EC) approves new biosimilars for osteoporosis and eye conditions, enhancing treatment options and ...
FDA approves Bosaya and Aukelso, expanding affordable denosumab biosimilars for osteoporosis and bone-related cancers, enhancing treatment options.
The Center for Biosimilars connects professionals with insights on biosimilars, health economics, regulatory outcomes, and ...
Biosimilars significantly reduce health care costs in Australia, enhancing access to biologics while driving price competition in the pharmaceutical market. The economic impact of biosimilars on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback